Although the results of this study suggest that the higher expression of HO-1 is associated with favorable survival outcomes after allo-HSCT, the higher expression of HO-1 has not been shown to affect the risk of disease relapse or the development of GVHD. The gene discussed is HMOX1; the disease is graft versus host disease.